钆匹醇用于健康兔与猪磁共振血管成像的对比增强性能评价
在健康兔与猪中比较钆匹醇与钆特酸葡胺用于腹部对比增强磁共振血管成像的增强性能;兔主动脉信号增幅随钆匹醇剂量线性相关,0.05 mmol Gd/kg钆匹醇的动脉信号增强与图像质量至少等同于0.1 mmol Gd/kg钆特酸葡胺。
要点
- 兔主动脉信号增幅与钆匹醇剂量线性相关(P=0.0010)。
- 猪MIP主动脉SNR钆匹醇0.05 mmol/kg较钆特酸葡胺0.1 mmol/kg高22%(P=0.3095)。
- 盲法定性偏好钆匹醇图像3/6、钆特酸葡胺1/6、无偏好2/6。
核心结论
- 钆匹醇0.05 mmol Gd/kg用于首过腹部CE-MRA可行,动脉信号增强与图像质量至少等同于钆特酸葡胺0.1 mmol Gd/kg。
研究设计与样本
- 健康兔研究:4.7 T轴位3D梯度回波序列,钆匹醇0.025、0.05、0.075、0.1 mmol Gd/kg或钆特酸葡胺0.1 mmol Gd/kg,每组n=5-6;健康猪交叉研究:6头猪,3 T腹部CE-MRA,钆匹醇0.05 mmol Gd/kg或钆特酸葡胺0.1 mmol Gd/kg,间隔1周。
诊断标准与关键数值
- 兔首过主动脉ΔSNR与钆匹醇剂量线性相关(P=0.0010);较钆特酸葡胺0.1 mmol Gd/kg,钆匹醇0.05、0.075、0.1 mmol Gd/kg的ΔSNR分别+63%(P=0.0731)、+78%(P=0.0081)、+72%(P=0.0773),0.025 mmol Gd/kg为+15%(P>0.9999)。
临床应用与阅片要点
- 作者结论认为钆匹醇0.05 mmol Gd/kg首过CE-MRA可行,动脉信号增强与图像质量至少等同于钆特酸葡胺0.1 mmol Gd/kg。
局限性
- 兔研究中钆匹醇0.05 mmol Gd/kg较钆特酸葡胺0.1 mmol Gd/kg的ΔSNR增加+63%但P=0.0731,未达统计学显著。
- 兔研究中钆匹醇0.1 mmol Gd/kg较钆特酸葡胺0.1 mmol Gd/kg的ΔSNR增加+72%但P=0.0773,未达统计学显著。
- 猪研究中钆匹醇0.05 mmol/kg较钆特酸葡胺0.1 mmol Gd/kg的MIP SNR高22%但P=0.3095,未达统计学显著。
- 定性偏好分析中钆匹醇图像3/6、钆特酸葡胺1/6、无偏好2/6,样本为6头猪。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Unexpected accumulations of gadolinium in various organs were reported after the administration of gadolinium-based contrast agents, making desirable to reduce the dose while maintaining equivalent diagnostic performance. The aim of this study was to evaluate the contrast enhancement performance of high relaxivity gadopiclenol compared with gadoterate meglumine in abdominal contrast-enhanced magnetic resonance angiography (CE-MRA).
MATERIALS AND METHODS: In a first study in healthy rabbits, axial 3D gradient echo sequences were applied at 4.7 T to study arterial enhancement as a function of gadopiclenol dose (0.025, 0.05, 0.075, and 0.1 mmol Gd/kg) or gadoterate meglumine at 0.1 mmol Gd/kg (n = 5-6/group). The increase in signal-to-noise ratio (ΔSNR) in the aorta at the first pass was measured and compared. In a second, crossover study in 6 healthy pigs, abdominal CE-MRA sequences were acquired at 3 T with gadopiclenol at 0.05 mmol Gd/kg or gadoterate meglumine at 0.1 mmol Gd/kg at a 1-week interval. Quantitatively on the maximum intensity projection (MIP) images, the mean MIP SNR within the aorta of both groups was compared. Qualitatively, a blinded comparison of the angiograms was performed by an experienced radiologist to determine the preferred contrast agent.
RESULTS: In the rabbit, ∆SNR is linearly correlated with the gadopiclenol dose ( P = 0.0010). Compared with gadoterate meglumine 0.1 mmol Gd/kg, an increase in the ∆SNR is observed after 0.05, 0.075, and 0.1 mmol Gd/kg of gadopiclenol (+63% P = 0.0731, +78% P = 0.0081, and +72% P = 0.0773, respectively), whereas at 0.025 mmol Gd/kg, ∆SNR is in the same range as with gadoterate meglumine 0.1 mmol Gd/kg (+15% P > 0.9999). In pigs, contrast enhancement after gadopiclenol at 0.05 mmol/kg is +22% superior to MIP SNR after gadoterate meglumine at 0.1 mmol Gd/kg ( P = 0.3095). Qualitatively, a preference was shown for gadopiclenol images (3/6) over the gadoterate meglumine examinations (1/6), with no preference being shown for the remainder (2/6).
CONCLUSIONS: First-pass CE-MRA is feasible with gadopiclenol at 0.05 mmol Gd/kg with at least the same arterial signal enhancement and image quality as gadoterate meglumine at 0.1 mmol Gd/kg.
引用
- Hugon G, Adriaensen H, Wintrebert M, et al. Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs. Invest Radiol. 2024. PMID: 38709660. doi:10.1097/RLI.0000000000001083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。